RxDoctor Payments Data

Mohammad Mahmud, MD

Internal Medicine · Corona, CANPI 1164513784

Payments from drug & device makers

$1,149,717in general payments, 2019–2025

Across 298 payments — averaging $3858.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$882K
  • Ironwood Pharmaceuticals, Inc$173K
  • Bausch Health US, LLC$87K
  • Pfizer$8K
  • Boston Scientific$20
$25,532in research payments, 2019–2025

Across 4 payments — averaging $6382.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$26K

What the payments were for

  • Food & beverage$20100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)262$881,864
Ironwood Pharmaceuticals, Inc19$172,618
Bausch Health US, LLC6$86,896
Pfizer10$8,320
Boston Scientific1$20

How this compares

$1,149,717 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$36,614
Medicare patients
274
Services billed
800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Albuterol Sulfate HfaAlbuterol Sulfate99$1,784
Methylprednisolone200$1,183
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst84$827
Betamethasone Dipropionate37$788
Ofloxacin44$596
Doxycycline Hyclate109$568
Azithromycin206$433
Cefdinir49$428
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav60$356
Baclofen126$274
Meloxicam116$188
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$166
Ondansetron Hcl31$161
Naproxen26$110
Clindamycin Hcl16$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPaxlovid$8,320$029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →